<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033058</url>
  </required_header>
  <id_info>
    <org_study_id>CHN2009CV005</org_study_id>
    <nct_id>NCT01033058</nct_id>
  </id_info>
  <brief_title>Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI</brief_title>
  <official_title>Effect of Intensive Statin Treatment on 90-day Prognosis of STEMI Patients Undergoing Emergency Primary PCI Compared With Usual Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, randomized, parallel, open-labeled, controlled study to find out
      whether STEMI patients undergoing emergency PCI can benefit from intensive atorvastatin
      treatment compared with routine treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ARMYDA-ACS, ARMYDA-RECAPTURE and NAPLES II demonstrated that in patients with ASP and NSTE
      ACS undergoing early PCI, loading dose of atorvastatin before early PCI led to a reduction of
      prei-PCI MI, recurrent CV events and mortality. While, theses studies included patients with
      non-ST-segment elevation ACS, requiring PCI; these results cannot be extrapolated directly to
      patients with ST-segment elevation MI, and these trials included patients sent to an early
      and selective PCI, but not those undergoing emergency revascularization;

      This study is designed to find out whether STEMI patients undergoing emergency PCI can
      benefit from intensive atorvastatin treatment compared with routine treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined endpoint of 90-day all cause morality, cardiac death, recurrent MI, recurrent symptomatic myocardiac ischemia, target vessel revascularization</measure>
    <time_frame>2009 Dec- 2011 Mar</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive statin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI</description>
    <arm_group_label>intensive statin treatment</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI</description>
    <arm_group_label>usual care</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-75 years old

          -  myocardiac ischemia symptom of index event appeared less than 12 hours before
             enrollment.

          -  ECG showed elevated ST segment in 3 or more contiguous leads

          -  diagnosed with acute STEMI

          -  eligible for primary PCI, and primary PCI is scheduled within 2 hours after enrollment

        Exclusion Criteria:

          -  allergic or experienced serious adverse reaction to HMG-CoA reductase

          -  pregnancy, lactation, or child bearing potential women without any effective
             contraception

          -  accompanied with malignant disease

          -  active hepatic disease or hepatic dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinchun Yang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chaoyang Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinchun Yang, Prof.</last_name>
    <phone>+86 10 85231937</phone>
    <email>yangxc@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Chaoyang</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanying Shen, Dr.</last_name>
      <phone>85201000</phone>
    </contact>
    <investigator>
      <last_name>Xinchun Yang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>December 23, 2009</last_update_submitted>
  <last_update_submitted_qc>December 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Yang Xinchun</name_title>
    <organization>Beijing Chaoyang Hospital</organization>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

